Transparency, IP Issues Dominate Discussion On WHO's Roadmap To Improve Drug Access
Executive Summary
Advocacy groups want the WHO's proposed roadmap on improving access to medicines to include stronger language on transparency of R&D costs, prices and revenues. The pharmaceutical industry, however, believes any forward-looking solution should rest upon strong IP protection.